4.6 Review

Structure-based drug repositioning: Potential and limits

期刊

SEMINARS IN CANCER BIOLOGY
卷 68, 期 -, 页码 192-198

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2020.01.010

关键词

Drug repositioning; Structure-based screening; Repurposed drugs

类别

向作者/读者索取更多资源

Drug repositioning is a strategy to assign new therapeutic purposes to known drugs, with many success cases in the market and more in experimental stage. Understanding drug-target interactions is crucial, and the availability of target data is a limiting factor for realizing the full potential of structural drug repositioning.
Drug repositioning, the assignment of new therapeutic purposes to known drugs, is an established strategy with many repurposed drugs on the market and many more at experimental stage. We review three use cases, a herpes drug with benefits in cancer, a cancer drug with potential in autoimmune disease, and a selective and an unspecific drug binding the same target (GPCR). We explore these use cases from a structural point of view focusing on a deep understanding of the underlying drug-target interactions. We review tools and data needed for such a drug-centric structural repositioning approach. Finally, we show that the availability of data on targets is an important limiting factor to realize the full potential of structural drug-repositioning.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据